Novartis Ag (NVSEF) Cash & Equivalents (2009 - 2025)

Novartis Ag has disclosed Cash & Equivalents across 12 years of filings, most recently posting $2.6 billion for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $2.6 billion, up 965.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.6 billion (up 965.7% YoY), and the FY2025 annual result was $2.6 billion, up 965.7% from the prior year.
• Cash & Equivalents came in at $2.6 billion for Q4 2025 at Novartis Ag, down from $6.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2000.0 billion in Q1 2024 to a low of $6.0 million in Q1 2021.
• The 5-year median for Cash & Equivalents is $648.0 million (2023), against an average of $121.3 billion.
• Across the five-year window, Cash & Equivalents jumped 12130.34% in 2023 and plunged 98.19% in 2024, its largest moves.
• Novartis Ag's Cash & Equivalents stood at $12.4 billion in 2021, then tumbled by 39.41% to $7.5 billion in 2022, then surged by 78.17% to $13.4 billion in 2023, then slumped by 98.19% to $242.0 million in 2024, then soared by 965.7% to $2.6 billion in 2025.
• The last three Cash & Equivalents figures came in at $2.6 billion (Q4 2025), $6.7 billion (Q2 2025), and $242.0 million (Q4 2024), per Business Quant data.